Sedat Gül/LinkedIn
Sep 5, 2026, 02:44
Sedat Gül: Is It Time to Reconsider the 24-Hour Antiplatelet Delay After Thrombolysis?
Sedat Gül, Assistant Professor at University of Nebraska Medical Center, shared a post on LinkedIn:
“I had the opportunity to comment in Annals of Internal Medicine on the TAPIS trial, which revisits the timing of antiplatelet therapy after thrombolysis in acute ischemic stroke.
While the findings may not be directly generalizable to the U.S. stroke population, TAPIS provides solid safety data and a signal of potential benefit with earlier initiation of antiplatelet therapy.”
Stay updated with Hemostasis Today.
-
Sep 5, 2026, 03:30Rob Maloney: Who Are the Real Experts? – The Quiet Resilience of the Bleeding Disorders Community
-
Sep 5, 2026, 03:26Project Elevate Her – Scaling Heights for Bleeding Disorders Awareness – WFH
-
Sep 5, 2026, 03:20Sarah Bassiony: How Do non-Specialists Learn Haematology? – Participate in Our Remote Study
-
Sep 5, 2026, 03:13Omid Seidizadeh: Uncovering the Genetic Architecture of Low Von Willebrand Factor
-
Sep 5, 2026, 03:07Luke McLaughlin: The First Community Article of the Haemophilia Rights Project
-
Sep 5, 2026, 03:00Panagiotis Christoforou: Proud to Contribute to Barts Health’s Leading Role in UK Clinical Trials
-
Sep 5, 2026, 02:51Kassiani Maria Nastouli: Honored to Be Cited in the New ESC Guidelines on the Management of CVD and CKD
-
Sep 5, 2026, 02:35Balaji Balagani: Exploring Stable vs Unstable vs Complete Coronary Block
-
Sep 5, 2026, 02:28N. Mariana S. Vasquez: Warm vs Cold Autoimmune Hemolytic Anemia for USMLE/NBME Questions